{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T07:34:29Z","timestamp":1795160069837,"version":"4.10.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cardiac allograft vasculopathy (CAV) is a major cause of morbidity and mortality following heart transplantation (HT). Reduced cardiovascular mortality and morbidity have been reported in non-HT patients treated with metformin. Given the high prevalence of type 2 diabetes mellitus (T2DM) in HT patients, we investigated the association between metformin therapy and cardiovascular outcomes after HT.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study population comprised 103 DM patients who had undergone HT between 1994 and 2018 and were prospectively followed-up. We excluded from the study patients with type 1 diabetes mellitus. Fifty-five HT patients (53%) in the cohort were treated with metformin. Clinical data were recorded on prospectively designed forms. The primary outcomes included CAV, survival, and the combined end-point of CAV or cardiovascular mortality.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Kaplan\u2013Meier survival analysis showed that the CAV rate at 20\u00a0years of follow-up was lower in DM patients treated with metformin than in those who were not (30 vs. 65%; log-rank p\u2009=\u20090.044). Similarly, the combined risk of CAV or cardiovascular mortality was lower in the metformin-treated patients than in those not receiving metformin (32 vs. 68%; log rank p\u2009=\u20090.01). Consistently, multivariate analysis adjusted for age and comorbidities showed that metformin therapy was independently associated with a significant 90% reduction (95% confidence interval 0.02\u20130.46, p\u2009=\u20090.003) in the risk for the development of CAV, and a 91% reduction (95% confidence interval 0.02\u20130.42; p\u2009=\u20090.003) in the risk for CAV or cardiovascular mortality.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In diabetic HT patients, metformin therapy is independently associated with a significant reduction in the long-term risk for CAV and the combined end-point of CAV or cardiovascular mortality after HT.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-019-0925-y","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T13:02:38Z","timestamp":1568638958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3292-821X","authenticated-orcid":false,"given":"Eilon","family":"Ram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Lavee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Tenenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Klempfner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique Z.","family":"Fisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Maor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Ovdat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Amunts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Sternik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Peled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,16]]},"reference":[{"key":"925_CR1","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.healun.2018.07.020","volume":"37","author":"DC Chambers","year":"2018","unstructured":"Chambers DC, Cherikh WS, Goldfarb SB, Hayes D Jr, Kucheryavaya AY, Toll AE, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-fifth adult lung and heart\u2013lung transplant report-2018; Focus theme: multiorgan transplantation. J Heart Lung Transplant. 2018;37:1169\u201383.","journal-title":"J Heart Lung Transplant"},{"key":"925_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jacc.2016.04.033","volume":"68","author":"S Chih","year":"2016","unstructured":"Chih S, Chong AY, Mielniczuk LM, Bhatt DL, Beanlands RS. Allograft vasculopathy: the Achilles\u2019 heel of heart transplantation. J Am Coll Cardiol. 2016;68:80\u201391.","journal-title":"J Am Coll Cardiol"},{"key":"925_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12933-017-0579-6","volume":"16","author":"W Eilenberg","year":"2019","unstructured":"Eilenberg W, Stojkovic S, Piechota-Polanczyk A, Kaider A, Kozakowski N, Weninger WJ, et al. Neutrophil gelatinase associated lipocalin (NGAL) is elevated in type 2 diabetics with carotid artery stenosis and reduced under metformin treatment. Cardiovasc Diabetol. 2017;16:98.","journal-title":"Cardiovasc Diabetol"},{"key":"925_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12933-017-0551-5","volume":"16","author":"A Younis","year":"2017","unstructured":"Younis A, Eskenazi D, Goldkorn R, Leor J, Naftali-Shani N, Fisman EZ, et al. The addition of vildagliptin to metformin prevents the elevation of interleukin 1\u03b2 in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study. Cardiovasc Diabetol. 2017;16:69.","journal-title":"Cardiovasc Diabetol"},{"key":"925_CR5","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.healun.2017.06.009","volume":"36","author":"Y Peled","year":"2017","unstructured":"Peled Y, Lavee J, Raichlin E, Katz M, Arad M, Kassif Y, et al. Metformin therapy reduces the risk of malignancy after heart transplantation. J Heart Lung Transplant. 2017;36:1350\u20137.","journal-title":"J Heart Lung Transplant"},{"key":"925_CR6","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1111\/j.1600-6143.2011.03550.x","volume":"11","author":"A Sharif","year":"2011","unstructured":"Sharif A. Should metformin be our antiglycemic agent of choice post-transplantation? Am J Transplant. 2011;11:1376\u201381.","journal-title":"Am J Transplant"},{"issue":"17","key":"925_CR7","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1136\/heartjnl-2018-314639","volume":"105","author":"X Yu","year":"2019","unstructured":"Yu X, Jiang D, Wang J, Wang R, Chen T, Wang K, et al. Metformin prescription and aortic aneurysm: systematic review and meta-analysis. Heart. 2019;105(17):1351\u20137.","journal-title":"Heart."},{"key":"925_CR8","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","volume":"60","author":"SJ Griffin","year":"2017","unstructured":"Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017;60:1620\u20139.","journal-title":"Diabetologia"},{"key":"925_CR9","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jacc.2006.04.088","volume":"48","author":"S Jadhav","year":"2006","unstructured":"Jadhav S, Ferrell W, Greer IA, Petrie JR, Cobbe SM, Sattar N. Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2006;48:956\u201363.","journal-title":"J Am Coll Cardiol"},{"key":"925_CR10","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1161\/RES.0000000000000104","volume":"118","author":"E Murphy","year":"2016","unstructured":"Murphy E, Ardehali H, Balaban RS, DiLisa F, Dorn GW 2nd, Kitsis RN, et al. Mitochondrial function, biology, and role in disease: a scientific statement from the American Heart Association. Circ Res. 2016;118:1960\u201391.","journal-title":"Circ Res"},{"key":"925_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12933-018-0663-6","volume":"17","author":"CW Chan","year":"2018","unstructured":"Chan CW, Yu CL, Lin JC, Hsieh YC, Lin CC, Hung CY, et al. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in type 2 diabetes patients: a nationwide cohort observational study. Cardiovasc Diabetol. 2018;17:20.","journal-title":"Cardiovasc Diabetol"},{"key":"925_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12933-017-0584-9","volume":"16","author":"SW Gillani","year":"2017","unstructured":"Gillani SW, Sulaiman SAS, Abdul MIM, Baig MR. Combined effect of metformin with ascorbic acid versus acetyl salicylic acid on diabetes-related cardiovascular complication; a 12-month single blind multicenter randomized control trial. Cardiovasc Diabetol. 2017;16:103.","journal-title":"Cardiovasc Diabetol"},{"key":"925_CR13","doi-asserted-by":"publisher","first-page":"542","DOI":"10.7326\/M15-3016","volume":"164","author":"JJ Chamberlain","year":"2016","unstructured":"Chamberlain JJ, Rhinehart AS, Shaefer CF Jr, Neuman A. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of medical care in diabetes. Ann Intern Med. 2016;164:542\u201352.","journal-title":"Ann Intern Med"},{"key":"925_CR14","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.healun.2010.05.017","volume":"29","author":"MR Mehra","year":"2010","unstructured":"Mehra MR, Crespo-Leiro MG, Dipchand A, Ensminger SM, Hiemann NE, Kobashigawa JA, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant. 2010;29:717\u201327.","journal-title":"J Heart Lung Transplant"},{"key":"925_CR15","volume-title":"R: a language and environment for statistical computing","author":"Team RDC","year":"2015","unstructured":"Team RDC. R: a language and environment for statistical computing. Vienna: Team RDC; 2015."},{"key":"925_CR16","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jchf.2017.08.021","volume":"5","author":"MM Kittleson","year":"2017","unstructured":"Kittleson MM, Kobashigawa JA. Cardiac transplantation: current outcomes and contemporary controversies. JACC Heart Fail. 2017;5:857\u201368.","journal-title":"JACC Heart Fail"},{"key":"925_CR17","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/01.TP.0000080981.90718.EB","volume":"76","author":"HA Valantine","year":"2003","unstructured":"Valantine HA. Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant \u201catheroma\u201d. Transplantation. 2003;76:891\u20139.","journal-title":"Transplantation"},{"key":"925_CR18","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.healun.2018.07.022","volume":"37","author":"KK Khush","year":"2018","unstructured":"Khush KK, Cherikh WS, Chambers DC, Goldfarb S, Hayes D Jr, Kucheryavaya AY, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-fifth adult heart transplantation report-2018; Focus theme: multiorgan transplantation. J Heart Lung Transplant. 2018;37:1155\u201368.","journal-title":"J Heart Lung Transplant"},{"key":"925_CR19","doi-asserted-by":"publisher","first-page":"1025893","DOI":"10.1155\/2018\/1025893","volume":"2018","author":"MG Cehic","year":"2018","unstructured":"Cehic MG, Nundall N, Greenfield JR, Macdonald PS. Management strategies for posttransplant diabetes mellitus after heart transplantation: a review. J Transplant. 2018;2018:1025893.","journal-title":"J Transplant"},{"key":"925_CR20","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.healun.2010.05.034","volume":"29","author":"MR Costanzo","year":"2010","unstructured":"Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914\u201356.","journal-title":"J Heart Lung Transplant"},{"key":"925_CR21","doi-asserted-by":"publisher","first-page":"979","DOI":"10.4158\/EP.14.8.979","volume":"14","author":"B Kurian","year":"2008","unstructured":"Kurian B, Joshi R, Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr Pract. 2008;14:979\u201384.","journal-title":"Endocr Pract"},{"key":"925_CR22","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854\u201365.","journal-title":"Lancet"},{"key":"925_CR23","unstructured":"Centers for Disease Control and Prevention, National diabetes Fact Sheet: National Estimates and general information on diabetes and prediabetes in the United States. 2011."},{"key":"925_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12933-018-0709-9","volume":"17","author":"FJ Dore","year":"2018","unstructured":"Dore FJ, Domingues CC, Ahmadi N, Kundu N, Kropotova Y, Houston S, et al. The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial. Cardiovasc Diabetol. 2018;17:65.","journal-title":"Cardiovasc Diabetol"},{"key":"925_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3389\/fphar.2019.00154","volume":"10","author":"H Loi","year":"2019","unstructured":"Loi H, Boal F, Tronchere H, Cinato M, Kramar S, Oleshchuk O, et al. Metformin protects the heart against hypertrophic and apoptotic remodeling after myocardial infarction. Front Pharmacol. 2019;10:154.","journal-title":"Front Pharmacol"},{"key":"925_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12933-017-0509-7","volume":"16","author":"A Mary","year":"2017","unstructured":"Mary A, Hartemann A, Liabeuf S, Aubert CE, Kemel S, Salem JE, et al. Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients. Cardiovasc Diabetol. 2017;16:24.","journal-title":"Cardiovasc Diabetol"},{"key":"925_CR27","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1093\/eurheartj\/ehv239","volume":"36","author":"E Ferrannini","year":"2015","unstructured":"Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36:2288\u201396.","journal-title":"Eur Heart J"},{"key":"925_CR28","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1111\/dom.13448","volume":"20","author":"DL Weir","year":"2018","unstructured":"Weir DL, Abrahamowicz M, Beauchamp ME, Eurich DT. Acute vs. cumulative benefits of metformin use in patients with type 2 diabetes and heart failure. Diabetes Obes Metab. 2018;20:2653\u201360.","journal-title":"Diabetes Obes Metab"},{"key":"925_CR29","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1161\/CIRCULATIONAHA.117.031735","volume":"137","author":"G Rena","year":"2018","unstructured":"Rena G, Lang CC. Repurposing metformin for cardiovascular disease. Circulation. 2018;137:422\u20134.","journal-title":"Circulation"},{"key":"925_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz203","author":"M Mohan","year":"2019","unstructured":"Mohan M, Al-Talabany S, McKinnie A, Mordi IR, Singh JSS, Gandy SJ, et al. A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. Eur Heart J. 2019. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehz203\n                    \n                  .","journal-title":"Eur Heart J."},{"key":"925_CR31","first-page":"9484717","volume":"2019","author":"Y Lu","year":"2019","unstructured":"Lu Y, Wang Y, Weng T, Chen Z, Sun X, Wei J, et al. Association between metformin use and coronary artery calcification in type 2 diabetic patients. J Diabetes Res. 2019;2019:9484717.","journal-title":"J Diabetes Res"},{"key":"925_CR32","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1158\/1078-0432.CCR-12-0694","volume":"18","author":"M Pollak","year":"2012","unstructured":"Pollak M. Metformin and pancreatic cancer: a clue requiring investigation. Clin Cancer Res. 2012;18:2723\u20135.","journal-title":"Clin Cancer Res"},{"key":"925_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12933-018-0715-y","volume":"17","author":"LB Steffensen","year":"2018","unstructured":"Steffensen LB, Feddersen S, Preil SR, Rasmussen LM. No detectable differential microRNA expression between non-atherosclerotic arteries of type 2 diabetic patients (treated or untreated with metformin) and non-diabetic patients. Cardiovasc Diabetol. 2018;17:72.","journal-title":"Cardiovasc Diabetol"},{"key":"925_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.redox.2017.08.018","volume":"14","author":"AR Cameron","year":"2018","unstructured":"Cameron AR, Logie L, Patel K, Erhardt S, Bacon S, Middleton P, et al. Metformin selectively targets redox control of complex I energy transduction. Redox Biol. 2018;14:187\u201397.","journal-title":"Redox Biol"},{"key":"925_CR35","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1161\/CIRCRESAHA.116.308445","volume":"119","author":"AR Cameron","year":"2016","unstructured":"Cameron AR, Morrison VL, Levin D, Mohan M, Forteath C, Beall C, et al. Anti-inflammatory effects of metformin irrespective of diabetes status. Circ Res. 2016;119:652\u201365.","journal-title":"Circ Res"},{"issue":"7","key":"925_CR36","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1097\/TP.0000000000002704","volume":"103","author":"AP Nikolova","year":"2019","unstructured":"Nikolova AP, Kobashigawa JA. Cardiac allograft vasculopathy\u2014the enduring enemy of cardiac transplantation. Transplantation. 2019;103(7):1338\u201348.","journal-title":"Transplantation"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0925-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-019-0925-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0925-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T23:07:45Z","timestamp":1600124865000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-019-0925-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,16]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["925"],"URL":"https:\/\/doi.org\/10.1186\/s12933-019-0925-y","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,16]]},"assertion":[{"value":"13 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional Ethical Committee (Protocol No 4257).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"118"}}